DOCSLIB.ORG

862F50a0ea63c82ca473bf845b5

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
862F50a0ea63c82ca473bf845b5 Brain region Type Enriched GO annotation Gene symbol AQR, ARMC7, BTBD9, HACL1, KCTD10, KCTD13, LSM6, MT2A, MYBPC1, POLD2, SRPX, TNFAIP1, USP25, EC Common type DNA replication, Protein catabolic process, Transport USP28, ZMYND19 EC Common type Transport KIAA1549, MBD5, MYO5B, RAB11A, RAB11FIP1, RAB11FIP2, RAB11FIP3, RAB11FIP4, RAB11FIP5, REPS1 ACD, BMP2K, C1orf63, CDK13, CLK3, CYLC2, DDX3Y, FOXJ3, GNL3L, GRPEL1, KIAA2022, MACROD2, Cellular component organization, Kinase activity, Localization, EC Common type NANOG, PAK1IP1, PCBP1, PCMT1, PLOD1, PLOD2, POT1, PRPS1L1, RASGEF1C, RBM15B, RPS7, RSBN1L, Response to stimulus, Transcription SALL1, SEC16A, TDRD6, TERF1, TERF2IP, TINF2, YTHDF1, YTHDF3, ZC3HAV1L, ZNF281 AGFG1, AKR1C3, ARIH1, ARIH2, BCL10, BFAR, BIRC2, BIRC3, BIRC6, BIRC7, C9orf89, CADPS2, CNOT4, DDX58, DIABLO, DTX1, DTX3L, DZIP3, EIF4E2, EML4, EPS15, EXTL3, FBXL19, FCHO2, GPR108, HLTF, HPCA, HTRA2, INF2, ISG15, KIAA1107, KIAA1797, LNX2, LOC147791, LRSAM1, LTN1, MAGEL2, MAP3K1, MARCH5, MARCH7, MC1R, MFN1, MGRN1, MID1, MID2, MKRN1, MKRN2, MKRN3, MRAP, MUL1, NAIP, PARP9, PCNP, PDZRN3, PJA2, PLCD4, RBCK1, RLIM, RMND5B, RNF10, RNF103, RNF11, RNF111, RNF114, DNA repair, Apoptosis, Protein catabolic process, Protein EC Common type RNF115, RNF125, RNF126, RNF128, RNF13, RNF130, RNF138, RNF14, RNF144A, RNF150, RNF165, RNF166, metabolic process, Protein modification process RNF167, RNF181, RNF182, RNF25, RNF26, RNF38, RNF4, RNF41, RSPRY1, SGCE, SH3RF2, STRADB, TMBIM6, TMEM189, TOPORS, TRAF7, TRIM2, TRIM25, TRIM26, TRIM27, TRIM32, TRIM35, TRIM39, TRIM8, UBA52, UBA6, UBE2D1, UBE2D2, UBE2D3, UBE2D4, UBE2E1, UBE2E2, UBE2E3, UBE2G1, UBE2J1, UBE2K, UBE2L3, UBE2L6, UBE2N, UBE2O, UBE2Q2, UBE2R2, UBE2T, UBE2V2, UBE2W, UBE2Z, UBE4A, UBOX5, UBTD1, UEVLD, UGP2, UHRF2, WDR91, XAF1, XIAP, ZNRF1, ZNRF3 ARL4A, BCAS2, CHD8, CSE1L, CTCF, CTNNBL1, KPNA1, KPNA2, KPNA4, PLAG1, PLRG1, PRPF19, RECQL, EC Common type RNA metabolic process, RNA splicing, Transport RPL22, ZNF143 ACCN2, AGAP2, C1orf116, CACNG2, CSPG4, GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIK3, GRIK5, GRIP1, EC Common type Synaptic transmission, Transport GRIPAP1, GRM3, HOMER1, MLF1, NUMBL, PICK1, PPM1A, RYR1, SDCBP, SOX4, STOML1 EC AD-specific type Cellular biosynthetic process AGL, CNTNAP4, GFPT1, GYG1, GYG2, GYS1, MAST3, NET1, PRKAB2, SH3PXD2A, STIM1, STIM2 EC AD-specific type Glycolysis, Metabolic process, Oxidation reduction DGKE, DLAT, PDHA1, PDHB, PDHX, PDK3 ADAP1, ANP32A, CHRM3, CSNK1A1, DKC1, ERF, LYPLA2, NME1, NUP88, PPP1R14A, PTMA, SET, SETBP1, EC AD-specific type Transport SHQ1, SYT9, THAP7, TNFRSF1B, TRPV1 EC Early-disrupted type Cell cycle, Protein modification process, Transport ACTN4, ATF1, CALM3, CAMK2A, CAMK2B, CAMK2D, MYO10, TRIM3, USP6NL EC Early-disrupted type Glycolysis C16orf45, ENO2, ENSA, HK1, MAP4, SNUPN, TUBA4A, ZNF259 ARHGAP10, ARHGAP44, CBLL1, CCDC104, CDC42, CDC42BPA, CDC42SE1, CDC42SE2, CLIP1, CSN2, Axon guidance, Cellular component organization, Kinase EC Early-disrupted type DOCK9, FGD1, FMNL2, HN1, HPS4, IQGAP1, MCF2L, MYL6B, OLFM2, OPHN1, PAK3, PAK6, PAK7, RAC1, activity ST13 EC Late-disrupted type MRNA stabilization, Protein folding, RNA catabolic process ARCN1, ETF1, GSPT1, GSPT2, MRPL39, PABPC1, PAIP1, PAIP2, PAN2, PAN3, PCBP1, PFDN2, PRMT6, VBP1 ACTB, ACTG1, ACTL6A, ACTR6, ACTR8, BRD8, C20orf20, CAP1, CAP2, CCDC87, CFL1, CFL2, DIP2A, DMAP1, DPCD, DSTN, E2F7, EP400, EPC1, EPC2, FKBP3, GEMIN7, H2AFV, H2AFZ, ING3, INO80, INO80B, Cell polarity, Cellular component movement, Chromatin EC Late-disrupted type INO80C, INO80E, KAT5, MBTD1, MCRS1, MORF4L1, MORF4L2, MRFAP1, MRFAP1L1, NCALD, NFRKB, modification, DNA repair, Growth, Kinase activity, Transcription NUFIP1, PALB2, PCBP1, PCYT1B, PIH1D1, PLA2G4A, PROM1, RUVBL1, RUVBL2, SENP6, SSH1, SSH2, TELO2, TFPT, TRIM68, TTI1, TUBA1A, VPS72, VSNL1, YEATS4, YY1, ZNF232, ZNHIT1 Cellular component organization, DNA repair, Response to EC Late-disrupted type APITD1, C17orf70, ERCC1, ERCC4, FANCF, FANCG, FANCL, HES1, RMI1, RTN2, SAMD3, STRA13, UBL7 stimulus ALDH3A2, ATP1A1, COBRA1, COX2, COX5A, COX5B, COX6B1, COX6C, FXYD1, RDBP, RPS26, SERF2, TH1L, EC Late-disrupted type Transcription TMEM141, TSR2, WHSC2 ARL2, BEST1, C22orf39, CCNG2, CCT2, CCT3, CCT4, CCT5, CCT6A, CCT6B, CCT7, CCT8, CEP350, CLDN12, Biological_process, Cell adhesion, Cell differentiation, DNA CTTNBP2, CTTNBP2NL, ECSIT, FAM40A, FAM40B, FGFR1OP, FGFR1OP2, HECTD1, IER2, IER5, IGBP1, replication, Growth, Kinase activity, Phosphorylation, Protein KLHDC2, MARCH1, MCC, PDCD10, PIM1, PPME1, PPP2CA, PPP2CB, PPP2R1A, PPP2R1B, PPP2R2B, EC Late-disrupted type catabolic process, Protein modification process, Response to PPP2R2D, PPP2R3A, PPP2R4, PPP2R5A, PPP2R5B, PPP2R5C, PPP2R5D, PPP2R5E, PRDX2, PRR14, RAB18, stimulus, Signaling, Small molecule metabolic process RFWD2, SKA2, SKIV2L2, SLMAP, STK25, STRN, STRN3, STRN4, TCP1, TUBA8, ZCCHC8, ZNF136, ZNF295, ZRANB1 Catalytic activity, Cell adhesion, Cell death, Cellular component organization, Membrane protein ectodomain proteolysis, Notch APBA2, APBA3, APBB2, APBB3, APP, BACE1, BGN, CIB1, CLSTN1, ICAM5, KCNIP4, NCSTN, PSEN1, EC Late-disrupted type receptor processing, Protein catabolic process, Protein PSEN2, PSENEN, SLK, YME1L1 processing, Proteolysis, Signaling Cell cycle, Cell division, Cellular component organization, EC Late-disrupted type FRMD4A, NCAPD3, NCAPH2, OLFM1, SMC2, SMC4, SNAP91, TRAF3IP1 Mitosis, Mitotic chromosome condensation ABI1, APBB1, APBB1IP, ASAP1, CHERP, COBL, CPSF6, CPSF7, CYFIP1, CYFIP2, DDX42, DDX46, DHX15, Endocytosis, Nuclear mRNA 3'-splice site recognition, Nuclear DNMBP, EVL, FMNL3, FYB, GAS7, GIN1, HTATSF1, MICALL1, NCK2, NCKAP1, PACSIN1, PACSIN2, PHF5A, EC Late-disrupted type mRNA splicing, via spliceosome, RNA metabolic process, RNA PRMT2, PRPF40A, RAPH1, RBM17, RCC2, RUFY2, SF1, SF3A1, SF3A2, SF3A3, SF3B1, SF3B14, SF3B2, splicing, Response to stimulus SF3B3, SF3B4, SF3B5, SMNDC1, TCERG1, TPM4, TSHZ1, TSHZ2, TSHZ3, VASP, WAS, WASF2, WBP11, WBP4, WIPF2, WIPF3, WWOX, YLPM1 EC Late-disrupted type Sensory perception of taste, Signaling ARHGEF18, GNB1, GNB2, GNB3, GNB4, GNB5, GNG10, GNG13, GNG3, GNG4, GNG5, KCNJ3 ADAT3, ANKRD12, ANLN, ATXN7, ATXN7L3, BRD2, BTAF1, CCDC101, CREM, DRAP1, ENY2, FAM48A, FOXF2, GTF2A1, GTF2A2, GTF2B, GTF2E1, GTF2E2, GTF2F1, GTF2H4, KAT2A, KLF5, KRT2, LAMB2, NFYB, Cell death, Cellular biosynthetic process, Histone H3 EC Late-disrupted type NR1D2, POU3F2, SAP130, SETD7, SND1, SUPT3H, SUPT7L, TADA1, TADA3, TAF1, TAF10, TAF11, TAF12, acetylation, Histone deubiquitination, Transcription TAF1L, TAF2, TAF3, TAF4, TAF4B, TAF5, TAF5L, TAF6, TAF7, TAF9, TAF9B, TBP, TBPL1, TCF12, THY1, TRIM24, TXNDC11, ZNF7 Anterior/posterior pattern formation, Cell proliferation, EC Late-disrupted type BTG1, BTG2, CNOT1, CNOT10, CNOT3, CNOT7, CNOT8, HMGN1, HOPX, HOXB9, PHTF1 Developmental process, Transcription EC Late-disrupted type RNA metabolic process NOVA1, POP1, POP4, POP5, POP7, RPP14, RPP30, RPP38, RPP40 ADRM1, ANKIB1, ASPRV1, C19orf60, CKMT2, CYB5B, DERA, DLD, DSP, DUSP14, HAUS7, HERC3, HERC6, HTR1E, INSIG2, JKAMP, LENG8, MAP3K5, MB, NUB1, PAAF1, PCID2, POTEKP, PSMA1, PSMA2, PSMA4, Cell cycle, Developmental process, Interspecies interaction PSMA6, PSMA7, PSMB2, PSMB3, PSMB5, PSMB6, PSMB7, PSMC1, PSMC2, PSMC3, PSMC4, PSMC5, EC Late-disrupted type between organisms, Protein catabolic process PSMC6, PSMD1, PSMD10, PSMD11, PSMD12, PSMD13, PSMD14, PSMD2, PSMD3, PSMD4, PSMD7, PSMD8, PTPN2, RNF185, RPN1, S100A14, S100A16, SAC3D1, SHFM1, SRXN1, TXN, TXNL1, UBE3C, UBLCP1, UBQLN2, UCHL5, USP14, USP37 Apoptosis, Cell cycle, Cell proliferation, Cellular biosynthetic EC Late-disrupted type CD74, CLEC2L, CRB1, EXT1, EXT2, FIBP, HYOU1, KIAA0528, MIF process, Macrophage activation, Ossification EC Late-disrupted type Cellular component organization, Transport NUP107, NUP37, NUP85, SEC13, SEC16B, SEC31A, SEH1L EC Late-disrupted type Cell cycle, Cell division, Mitosis, Protein modification process CDC42EP3, SEPT2, SEPT6, SEPT7, SEPT9, STMN1 EC Late-disrupted type Transport ALDOA, ALDOC, ATP6V1E1, ATP6V1G1, ATP6V1G2, ATP6V1H Apoptosis, Interspecies interaction between organisms, EC Late-disrupted type BNIP3, BNIP3L, CD47, DOK5, HLA-DPB1, PKMYT1, ROBO2, STEAP3, TMEM11, TRIM13 Response to stimulus, Survival gene product expression EC Late-disrupted type Protein modification process, Transport COG1, COG2, COG3, COG4, COG5, COG6, COG7 EC Late-disrupted type Attachment of GPI anchor to protein GPAA1, PIGK, PIGS, PIGT, ULBP2 EC Late-disrupted type Cellular biosynthetic process, Protein modification process DPM1, DPM2, DPM3, PIGA, PIGC, PIGH, PIGP, PIGQ EC Late-disrupted type Biological_process MPDZ, PLEKHA1, PLEKHA2 BCAP29, BCAP31, CABLES2, CDK3, CDK5, CPLX1, CPLX2, DOC2A, EHD3, ITSN1, OSBP, PRRT2, SCAMP1, Calcium ion-dependent exocytosis, Exocytosis, Membrane SCAMP2, SLC38A2, SLC6A1, SNAP23, SNAP25, SNAP29, SNTG1, SRCIN1, STX11, STX12, STX17, STX1A, EC Late-disrupted type fusion, Secretion, Synaptic transmission, Synaptic vesicle STX1B, STX2, STX3, STX4, STXBP1, STXBP3, STXBP5, SV2C, SYT1, SYT3, TNFRSF21, UNC13B, VAMP1, docking during exocytosis, Transport VAMP2, VAMP3, VAMP7, VAPA, VAPB MRNA cleavage, MRNA polyadenylation, Nuclear mRNA CDC73, CNTNAP2, CPSF1, CPSF2, CPSF3, CPSF4, CSTF1, CSTF2, CSTF2T, CSTF3, CTR9, FIP1L1, HSF2BP, EC Late-disrupted type splicing, via spliceosome, RNA metabolic process, LEO1, NOL8, PAF1, RRAGA, RRAGB, RRAGC, RRAGD, RTF1, SUPT6H, SYMPK, TCEA1, TTC37, WDR61 Transcription Angiogenesis, Cell differentiation, Cell migration, Cell ABI2, ABL1, ABL2, AEBP1, AP3S1, AREG, ARHGAP17,
Load more

Recommended publications
  • Genome-Wide Analysis of Transcriptional Bursting-Induced Noise in Mammalian Cells
    bioRxiv preprint doi: https://doi.org/10.1101/736207; this version posted August 15, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Title: Genome-wide analysis of transcriptional bursting-induced noise in mammalian cells Authors: Hiroshi Ochiai1*, Tetsutaro Hayashi2, Mana Umeda2, Mika Yoshimura2, Akihito Harada3, Yukiko Shimizu4, Kenta Nakano4, Noriko Saitoh5, Hiroshi Kimura6, Zhe Liu7, Takashi Yamamoto1, Tadashi Okamura4,8, Yasuyuki Ohkawa3, Itoshi Nikaido2,9* Affiliations: 1Graduate School of Integrated Sciences for Life, Hiroshima University, Higashi-Hiroshima, Hiroshima, 739-0046, Japan 2Laboratory for Bioinformatics Research, RIKEN BDR, Wako, Saitama, 351-0198, Japan 3Division of Transcriptomics, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Fukuoka, 812-0054, Japan 4Department of Animal Medicine, National Center for Global Health and Medicine (NCGM), Tokyo, 812-0054, Japan 5Division of Cancer Biology, The Cancer Institute of JFCR, Tokyo, 135-8550, Japan 6Graduate School of Bioscience and Biotechnology, Tokyo Institute of Technology, Yokohama, Kanagawa, 226-8503, Japan 7Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA, 20147, USA 8Section of Animal Models, Department of Infectious Diseases, National Center for Global Health and Medicine (NCGM), Tokyo, 812-0054, Japan 9Bioinformatics Course, Master’s/Doctoral Program in Life Science Innovation (T-LSI), School of Integrative and Global Majors (SIGMA), University of Tsukuba, Wako, 351-0198, Japan *Corresponding authors Corresponding authors e-mail addresses Hiroshi Ochiai, [email protected] Itoshi Nikaido, [email protected] bioRxiv preprint doi: https://doi.org/10.1101/736207; this version posted August 15, 2019.
    [Show full text]
  • Nucleolin and Its Role in Ribosomal Biogenesis
    NUCLEOLIN: A NUCLEOLAR RNA-BINDING PROTEIN INVOLVED IN RIBOSOME BIOGENESIS Inaugural-Dissertation zur Erlangung des Doktorgrades der Mathematisch-Naturwissenschaftlichen Fakultät der Heinrich-Heine-Universität Düsseldorf vorgelegt von Julia Fremerey aus Hamburg Düsseldorf, April 2016 2 Gedruckt mit der Genehmigung der Mathematisch-Naturwissenschaftlichen Fakultät der Heinrich-Heine-Universität Düsseldorf Referent: Prof. Dr. A. Borkhardt Korreferent: Prof. Dr. H. Schwender Tag der mündlichen Prüfung: 20.07.2016 3 Die vorgelegte Arbeit wurde von Juli 2012 bis März 2016 in der Klinik für Kinder- Onkologie, -Hämatologie und Klinische Immunologie des Universitätsklinikums Düsseldorf unter Anleitung von Prof. Dr. A. Borkhardt und in Kooperation mit dem ‚Laboratory of RNA Molecular Biology‘ an der Rockefeller Universität unter Anleitung von Prof. Dr. T. Tuschl angefertigt. 4 Dedicated to my family TABLE OF CONTENTS 5 TABLE OF CONTENTS TABLE OF CONTENTS ............................................................................................... 5 LIST OF FIGURES ......................................................................................................10 LIST OF TABLES .......................................................................................................12 ABBREVIATION .........................................................................................................13 ABSTRACT ................................................................................................................19 ZUSAMMENFASSUNG
    [Show full text]
  • Human Genome Center [150-177.Pdf]
    150 Human Genome Center Laboratory of Genome Database Laboratory of Sequence Analysis ゲノムデータベース分野 シークエンスデータ情報処理分野 Professor Minoru Kanehisa, Ph. D. 教 授 理学博士 金 久 實 Research Associate Toshiaki Katayama, M. Sc. 助 手 理学修士 片山俊明 Research Associate Shuichi Kawashima, M. Sc. 助 手 理学修士 川島秀一 Lecturer Tetsuo Shibuya, Ph. D. 講 師 理学博士 渋谷哲朗 Research Associate Michihiro Araki, Ph. D. 助 手 薬学博士 荒木通啓 Owing to continuous developments of high-throughput experimental technologies, ever-increasing amounts of data are being generated in functional genomics and proteomics. We are developing a new generation of databases and computational technologies, beyond the traditional genome databases and sequence analysis tools, for making full use of such large-scale data in biomedical applications, espe- cially for elucidating cellular functions as behaviors of complex interaction systems. 1. Comprehensive repository for community to make the system consistent with the existing genome annotation open standards. Thus, the contents of the KEGG DAS server can be accessed programatically by Toshiaki Katayama and Minoru Kanehisa the DAS protocol and graphically in a web browser using GBrowse. BioDAS, which is an KEGG DAS is a DAS (Distributed Annotation XML over HTTP data retrieving protocol, en- System) service for all organisms in the ables the user to write various kinds of auto- GENOME and GENES databases in KEGG mated programs for analyzing genome se- (Kyoto Encyclopedia of Genes and Genomes). It quences and annotations. For example, by com- started as part of the standardization efforts bining KEGG DAS with KEGG API, a program along with KEGG API and KGML, which are a to retrieve upstream sequences of a given set of SOAP based KEGG web service and XML repre- genes with similar expression patterns on the sentation of KEGG pathways, respectively.
    [Show full text]
  • Large-Scale Rnai Screening Uncovers New Therapeutic Targets in the Human Parasite
    bioRxiv preprint doi: https://doi.org/10.1101/2020.02.05.935833; this version posted February 6, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 1 Large-scale RNAi screening uncovers new therapeutic targets in the human parasite 2 Schistosoma mansoni 3 4 Jipeng Wang1*, Carlos Paz1*, Gilda Padalino2, Avril Coghlan3, Zhigang Lu3, Irina Gradinaru1, 5 Julie N.R. Collins1, Matthew Berriman3, Karl F. Hoffmann2, James J. Collins III1†. 6 7 8 1Department of Pharmacology, UT Southwestern Medical Center, Dallas, Texas 75390 9 2Institute of Biological, Environmental and Rural Sciences (IBERS), Aberystwyth University, 10 Aberystwyth, Wales, UK. 11 3Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, UK 12 *Equal Contribution 13 14 15 16 17 18 19 20 21 22 23 †To whom correspondence should be addressed 24 [email protected] 25 UT Southwestern Medical Center 26 Department of Pharmacology 27 6001 Forest Park. Rd. 28 Dallas, TX 75390 29 United States of America bioRxiv preprint doi: https://doi.org/10.1101/2020.02.05.935833; this version posted February 6, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 30 ABSTRACT 31 Schistosomes kill 250,000 people every year and are responsible for serious morbidity in 240 32 million of the world’s poorest people.
    [Show full text]
  • Analysis of Genomic Aberrations and Gene Expression Profiling Identifies
    Citation: Blood Cancer Journal (2011) 1, e40; doi:10.1038/bcj.2011.39 & 2011 Macmillan Publishers Limited All rights reserved 2044-5385/11 www.nature.com/bcj ORIGINAL ARTICLE Analysis of genomic aberrations and gene expression profiling identifies novel lesions and pathways in myeloproliferative neoplasms KL Rice1, X Lin1, K Wolniak1, BL Ebert2, W Berkofsky-Fessler3, M Buzzai4, Y Sun5,CXi5, P Elkin5, R Levine6, T Golub7, DG Gilliland8, JD Crispino1, JD Licht1 and W Zhang5 1Division of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA; 2Division of Hematology, Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USA; 3Translational Research Sciences, Hoffmann-La Roche, Inc., Nutley, NJ, USA; 4Oncology, Novartis, Origgio, VA, Italy; 5Division of Hematology/ Oncology, Department of Medicine, Center of Biomedical Informatics, Mount Sinai School of Medicine, New York, NY, USA; 6Human Oncology and Pathogenesis Program and Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; 7The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA and 8Oncology, Merck Research Laboratories, North Wales, PA, USA Polycythemia vera (PV), essential thrombocythemia and by a recurrent mutation, JAK2V617F, which is present in B95% primary myelofibrosis, are myeloproliferative neoplasms of patients with PV, B65% with PMF and B55% with ET.2 JAK2 (MPNs) with distinct clinical features and are associated with is one member of the Janus family of non-receptor tyrosine the JAK2V617F mutation. To identify genomic anomalies involved in the pathogenesis of these disorders, we profiled kinases that transduces signals downstream of type I and II 87 MPN patients using Affymetrix 250K single-nucleotide cytokine receptors via signal transducer and activators of polymorphism (SNP) arrays.
    [Show full text]
  • Dissertation
    Regulation of gene silencing: From microRNA biogenesis to post-translational modifications of TNRC6 complexes DISSERTATION zur Erlangung des DOKTORGRADES DER NATURWISSENSCHAFTEN (Dr. rer. nat.) der Fakultät Biologie und Vorklinische Medizin der Universität Regensburg vorgelegt von Johannes Danner aus Eggenfelden im Jahr 2017 Das Promotionsgesuch wurde eingereicht am: 12.09.2017 Die Arbeit wurde angeleitet von: Prof. Dr. Gunter Meister Johannes Danner Summary ‘From microRNA biogenesis to post-translational modifications of TNRC6 complexes’ summarizes the two main projects, beginning with the influence of specific RNA binding proteins on miRNA biogenesis processes. The fate of the mature miRNA is determined by the incorporation into Argonaute proteins followed by a complex formation with TNRC6 proteins as core molecules of gene silencing complexes. miRNAs are transcribed as stem-loop structured primary transcripts (pri-miRNA) by Pol II. The further nuclear processing is carried out by the microprocessor complex containing the RNase III enzyme Drosha, which cleaves the pri-miRNA to precursor-miRNA (pre-miRNA). After Exportin-5 mediated transport of the pre-miRNA to the cytoplasm, the RNase III enzyme Dicer cleaves off the terminal loop resulting in a 21-24 nt long double-stranded RNA. One of the strands is incorporated in the RNA-induced silencing complex (RISC), where it directly interacts with a member of the Argonaute protein family. The miRNA guides the mature RISC complex to partially complementary target sites on mRNAs leading to gene silencing. During this process TNRC6 proteins interact with Argonaute and recruit additional factors to mediate translational repression and target mRNA destabilization through deadenylation and decapping leading to mRNA decay.
    [Show full text]
  • Role and Regulation of the P53-Homolog P73 in the Transformation of Normal Human Fibroblasts
    Role and regulation of the p53-homolog p73 in the transformation of normal human fibroblasts Dissertation zur Erlangung des naturwissenschaftlichen Doktorgrades der Bayerischen Julius-Maximilians-Universität Würzburg vorgelegt von Lars Hofmann aus Aschaffenburg Würzburg 2007 Eingereicht am Mitglieder der Promotionskommission: Vorsitzender: Prof. Dr. Dr. Martin J. Müller Gutachter: Prof. Dr. Michael P. Schön Gutachter : Prof. Dr. Georg Krohne Tag des Promotionskolloquiums: Doktorurkunde ausgehändigt am Erklärung Hiermit erkläre ich, dass ich die vorliegende Arbeit selbständig angefertigt und keine anderen als die angegebenen Hilfsmittel und Quellen verwendet habe. Diese Arbeit wurde weder in gleicher noch in ähnlicher Form in einem anderen Prüfungsverfahren vorgelegt. Ich habe früher, außer den mit dem Zulassungsgesuch urkundlichen Graden, keine weiteren akademischen Grade erworben und zu erwerben gesucht. Würzburg, Lars Hofmann Content SUMMARY ................................................................................................................ IV ZUSAMMENFASSUNG ............................................................................................. V 1. INTRODUCTION ................................................................................................. 1 1.1. Molecular basics of cancer .......................................................................................... 1 1.2. Early research on tumorigenesis ................................................................................. 3 1.3. Developing
    [Show full text]
  • A Transcriptional Signature of Postmitotic Maintenance in Neural Tissues
    Neurobiology of Aging 74 (2019) 147e160 Contents lists available at ScienceDirect Neurobiology of Aging journal homepage: www.elsevier.com/locate/neuaging Postmitotic cell longevityeassociated genes: a transcriptional signature of postmitotic maintenance in neural tissues Atahualpa Castillo-Morales a,b, Jimena Monzón-Sandoval a,b, Araxi O. Urrutia b,c,*, Humberto Gutiérrez a,** a School of Life Sciences, University of Lincoln, Lincoln, UK b Milner Centre for Evolution, Department of Biology and Biochemistry, University of Bath, Bath, UK c Instituto de Ecología, Universidad Nacional Autónoma de México, Ciudad de México, Mexico article info abstract Article history: Different cell types have different postmitotic maintenance requirements. Nerve cells, however, are Received 11 April 2018 unique in this respect as they need to survive and preserve their functional complexity for the entire Received in revised form 3 October 2018 lifetime of the organism, and failure at any level of their supporting mechanisms leads to a wide range of Accepted 11 October 2018 neurodegenerative conditions. Whether these differences across tissues arise from the activation of Available online 19 October 2018 distinct cell typeespecific maintenance mechanisms or the differential activation of a common molecular repertoire is not known. To identify the transcriptional signature of postmitotic cellular longevity (PMCL), Keywords: we compared whole-genome transcriptome data from human tissues ranging in longevity from 120 days Neural maintenance Cell longevity to over 70 years and found a set of 81 genes whose expression levels are closely associated with Transcriptional signature increased cell longevity. Using expression data from 10 independent sources, we found that these genes Functional genomics are more highly coexpressed in longer-living tissues and are enriched in specific biological processes and transcription factor targets compared with randomly selected gene samples.
    [Show full text]
  • Evolutionary Fate of Retroposed Gene Copies in the Human Genome
    Evolutionary fate of retroposed gene copies in the human genome Nicolas Vinckenbosch*, Isabelle Dupanloup*†, and Henrik Kaessmann*‡ *Center for Integrative Genomics, University of Lausanne, Ge´nopode, 1015 Lausanne, Switzerland; and †Computational and Molecular Population Genetics Laboratory, Zoological Institute, University of Bern, 3012 Bern, Switzerland Communicated by Wen-Hsiung Li, University of Chicago, Chicago, IL, December 30, 2005 (received for review December 14, 2005) Given that retroposed copies of genes are presumed to lack the and rodent genomes (7–12). In addition, three recent studies regulatory elements required for their expression, retroposition using EST data (13, 14) and tiling-microarray data from chro- has long been considered a mechanism without functional rele- mosome 22 (15) indicated that retrocopy transcription may be vance. However, through an in silico assay for transcriptional widespread, although these surveys were limited, and potential activity, we identify here >1,000 transcribed retrocopies in the functional implications were not addressed. human genome, of which at least Ϸ120 have evolved into bona To further explore the functional significance of retroposition fide genes. Among these, Ϸ50 retrogenes have evolved functions in the human genome, we systematically screened for signatures in testes, more than half of which were recruited as functional of selection related to retrocopy transcription. Our results autosomal counterparts of X-linked genes during spermatogene- suggest that retrocopy transcription is not rare and that the sis. Generally, retrogenes emerge ‘‘out of the testis,’’ because they pattern of transcription of human retrocopies has been pro- are often initially transcribed in testis and later evolve stronger and foundly shaped by natural selection, acting both for and against sometimes more diverse spatial expression patterns.
    [Show full text]
  • WO 2012/174282 A2 20 December 2012 (20.12.2012) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/174282 A2 20 December 2012 (20.12.2012) P O P C T (51) International Patent Classification: David [US/US]; 13539 N . 95th Way, Scottsdale, AZ C12Q 1/68 (2006.01) 85260 (US). (21) International Application Number: (74) Agent: AKHAVAN, Ramin; Caris Science, Inc., 6655 N . PCT/US20 12/0425 19 Macarthur Blvd., Irving, TX 75039 (US). (22) International Filing Date: (81) Designated States (unless otherwise indicated, for every 14 June 2012 (14.06.2012) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, English (25) Filing Language: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, Publication Language: English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, (30) Priority Data: KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, 61/497,895 16 June 201 1 (16.06.201 1) US MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 61/499,138 20 June 201 1 (20.06.201 1) US OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, 61/501,680 27 June 201 1 (27.06.201 1) u s SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, 61/506,019 8 July 201 1(08.07.201 1) u s TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • STRIPAK Complexes in Cell Signaling and Cancer
    Oncogene (2016), 1–9 © 2016 Macmillan Publishers Limited All rights reserved 0950-9232/16 www.nature.com/onc REVIEW STRIPAK complexes in cell signaling and cancer Z Shi1,2, S Jiao1 and Z Zhou1,3 Striatin-interacting phosphatase and kinase (STRIPAK) complexes are striatin-centered multicomponent supramolecular structures containing both kinases and phosphatases. STRIPAK complexes are evolutionarily conserved and have critical roles in protein (de) phosphorylation. Recent studies indicate that STRIPAK complexes are emerging mediators and regulators of multiple vital signaling pathways including Hippo, MAPK (mitogen-activated protein kinase), nuclear receptor and cytoskeleton remodeling. Different types of STRIPAK complexes are extensively involved in a variety of fundamental biological processes ranging from cell growth, differentiation, proliferation and apoptosis to metabolism, immune regulation and tumorigenesis. Growing evidence correlates dysregulation of STRIPAK complexes with human diseases including cancer. In this review, we summarize the current understanding of the assembly and functions of STRIPAK complexes, with a special focus on cell signaling and cancer. Oncogene advance online publication, 15 February 2016; doi:10.1038/onc.2016.9 INTRODUCTION in the central nervous system and STRN4 is mostly abundant in Recent proteomic studies identified a group of novel multi- the brain and lung, whereas STRN3 is ubiquitously expressed in 5–9 component complexes named striatin (STRN)-interacting phos- almost all tissues. STRNs share a
    [Show full text]
  • Essential Genes Shape Cancer Genomes Through Linear Limitation of Homozygous Deletions
    ARTICLE https://doi.org/10.1038/s42003-019-0517-0 OPEN Essential genes shape cancer genomes through linear limitation of homozygous deletions Maroulio Pertesi1,3, Ludvig Ekdahl1,3, Angelica Palm1, Ellinor Johnsson1, Linnea Järvstråt1, Anna-Karin Wihlborg1 & Björn Nilsson1,2 1234567890():,; The landscape of somatic acquired deletions in cancer cells is shaped by positive and negative selection. Recurrent deletions typically target tumor suppressor, leading to positive selection. Simultaneously, loss of a nearby essential gene can lead to negative selection, and introduce latent vulnerabilities specific to cancer cells. Here we show that, under basic assumptions on positive and negative selection, deletion limitation gives rise to a statistical pattern where the frequency of homozygous deletions decreases approximately linearly between the deletion target gene and the nearest essential genes. Using DNA copy number data from 9,744 human cancer specimens, we demonstrate that linear deletion limitation exists and exposes deletion-limiting genes for seven known deletion targets (CDKN2A, RB1, PTEN, MAP2K4, NF1, SMAD4, and LINC00290). Downstream analysis of pooled CRISPR/Cas9 data provide further evidence of essentiality. Our results provide further insight into how the deletion landscape is shaped and identify potentially targetable vulnerabilities. 1 Hematology and Transfusion Medicine Department of Laboratory Medicine, BMC, SE-221 84 Lund, Sweden. 2 Broad Institute, 415 Main Street, Cambridge, MA 02142, USA. 3These authors contributed equally: Maroulio Pertesi, Ludvig Ekdahl. Correspondence and requests for materials should be addressed to B.N. (email: [email protected]) COMMUNICATIONS BIOLOGY | (2019) 2:262 | https://doi.org/10.1038/s42003-019-0517-0 | www.nature.com/commsbio 1 ARTICLE COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-019-0517-0 eletion of chromosomal material is a common feature of we developed a pattern-based method to identify essential genes Dcancer genomes1.
    [Show full text]